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Abstract
Uterine fibroids are extremely common, with major surgery the current main management option;
uterine artery embolisation is an alternative, but risks to fertility are unclear. Minimally invasive
procedures are becoming more commonly performed via both the hysteroscope and laparoscope,
minimising recovery time for patients. Recently, small doses of progesterone receptor modulators
(mifepristone and asoprisnil) have been shown to be effective in reducing menstrual blood loss and
fibroid size. Progress from here should include the development of a well-tolerated oral preparation
that will maintain fertility.
Introduction and context
Fibroids are present in up to 70% of women of
reproductive age [1]. Although many women with
fibroids are asymptomatic, others find they cause a
major disruption to daily life. There is evidence to
implicate a genetic predisposition; monozygotic female
twins are twice as likely to be concordant for hyster-
ectomy and/or hospitalization for fibroids as dizygotic
twins [2]. In a recent genetic study with sister-pairs with
fibroids, the embryonic proliferation modulatorHMGA2
gene was identified as a potential gene associated with a
predisposition for fibroids [3].
The mechanism(s) for fibroid growth is an area of much
research interest. Matsuo et al. [4] reported greater
cellular levels of the anti-apoptotic protein Bcl-2 in
leiomyoma cells than in normal myometrium. The sex
steroids oestrogen and progesterone have a role in
fibroid growth during the reproductive years, with
fibroids regressing after menopause. There is biochem-
ical, clinical, and pharmacological evidence to support a
role for progesterone in the pathogenesis of fibroids.
Fibroids have increased concentrations of both isoforms
of the progesterone receptor (PR-A and PR-B) [5].
The main associated symptoms are often problematic;
heavy menstrual bleeding [5,6] may result in severe
anaemia and social embarrassment and the presence of a
pelvic mass may lead to marked discomfort, abdominal
distension, and pressure-related bladder symptoms [7].
Additionally, distortion of the uterine cavity may result
in subfertility. Submucosal fibroids have been shown to
decrease pregnancy rates and so removal of such fibroids
where subfertility is an issue may be considered [8],
however, subserosal fibroids do not appear to be related
to fertility. Intramural fibroids are thought to decrease
fertility: although there is a lack of randomised trials, it
has been shown that, with in vitro fertilisation, there is a
reduced delivery rate in patients with untreated fibroids
but no change to delivery rate in those having had a
myomectomy [9].
The mainstay of present management for large sympto-
matic fibroids is surgery – hysterectomy or myomect-
omy. These are both major abdominal operations with
associated risks and prolonged recovery time. Uterine
artery embolisation (UAE) carries a risk of pelvic
infection and there is limited evidence regarding the
risks for future pregnancies [10-12].
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The levonorgestrel-releasing intrauterine system [LNG-
IUS, Mirena® (Bayer Schering Pharma)], although highly
effective as a treatment for heavy menstrual bleeding,
often fails if the uterine cavity is markedly enlarged or
distorted by fibroids. There is no evidence to show that a
LNG-IUS reduces fibroid size [13]. Gonadotrophin-
releasing hormone analogues can reduce the size of
fibroids by around 30%, but this should be regarded as a
short-term or pre-operative mode of management as the
resulting hypo-oestrogenic state can result in osteoporo-
sis if prolonged use occurs. In addition, the fibroids tend
to re-grow when such treatment is ceased [14].
Recent advances
The randomised clinical ‘EMMY’ (EMbolisation versus
HysterectoMY) multi-centre randomised control trial
prospectively looked at health-related quality of life
outcomes for hysterectomy and UAE at intervals up to
24 months, with regards to mental and physical health,
urinary function, and overall patient satisfaction. The
only significant difference between the groups was that
patients who underwent hysterectomy were more
satisfied with the received treatment than women who
underwent UAE [15].
The ‘HOPEFUL’ (Hysterectomy Or Percutaneous Embo-
lisation For Uterine Leiomyomata) study, a retrospective
multi-centre cohort study, assessed the treatment of
symptomatic uterine fibroids with either hysterectomy or
UAE and compared efficacy, safety, and cost-effective-
ness. Complications and cost were less in the UAE group,
even when retreatment (with uterine preservation) was
taken into consideration [16].
Women undergoing UAE (compared to hysterectomy for
symptomatic uterine fibroids in a randomised trial) have
been reported to have a faster recovery time but were at
risk of treatment failure in 9-20% of cases [12]. Ovarian
reserve may be affected by both hysterectomy and UAE.
Although permanent loss of ovarian function after UAE
usually affects those aged over 45, there may be impaired
ovarian function in younger patients [17]. This issue
needs to be considered as some women wishing to
maintain their fertility opt for UAE.
A recent prospective observational study evaluating long-
term efficacy and complications of UAE after 5-7 years
has shown that this is a beneficial treatment for women
wishing to avoid hysterectomy (satisfaction rate of 88%)
[18,19].
Hysteroscopic myomectomy is now the standard mini-
mally invasive surgical procedure for treating submuco-
sal fibroids. It is safe and effective and avoids opening
the uterine cavity [20]. Hysteroscopic removal of
submucosal fibroids appears to be of benefit where
infertility is an issue [8]. A recent prospective randomised
matched control trial found that hysteroscopic myo-
mectomy for submucous fibroids in women with
unexplained primary infertility improved pregnancy
rates [21]. The use of smaller diameter hysteroscopes
with working channels and bipolar technology may
remove the need for any anaesthetic and give the option
of such procedures being conducted in the outpatient
setting when the fibroids are small. The vaginoscopic, ‘no
touch’ approach removes the need for cervical dilatation,
a tenaculum, or even a speculum. Where the theatre
setting with general anaesthetic is indicated, pre-opera-
tive vaginal misoprostol has been shown to reduce the
need for cervical dilation, and to minimise operative
difficulties and cervical complications [22].
Minimally invasive abdominal procedures offer many
advantages over open techniques. A randomised trial [23]
comparing laparotomy, mini-laparotomy, and laparo-
scopic-assisted mini-laparotomy for myomectomy has
shown similar operating times. Laparoscopic-assisted
mini-laparotomy, however, offered a reduced time of
paralytic ileus and quicker discharge from hospital [23].
Laparoscopic myomectomy has also been shown to result
in reduced post-operative pain and requirements for
analgesia compared with laparotomy in the first 3 days
after surgery [24]. However, open myomectomy is some-
times the procedure of choice where the fibroid uterus is
large and fertility is desired [25]. A recent prospective
randomised control trial [26] has shown that the triple
tourniquet technique (applied to the uterine and ovarian
vessels) to temporarily occlude uterine blood supply,
thereby keeping intra-operative blood loss to a minimum
and reducing morbidity for the patient, is more effective
than pre-operative gonadotrophin-releasing hormone
analogues [26].
Progesterone receptor modulators have been demon-
strated to be effective in the management of sympto-
matic uterine fibroids [27]. Eisinger et al. [28] found low
dose (both 5 mg and 10 mg) mifepristone administered
daily for 6 months resulted in comparable fibroid
regression. A recent randomised controlled trial supports
this finding [29]; 100 women were randomised to either
5 mg or 10 mg of daily mifepristone for 3 months. Trans-
abdominal ultrasound scan was performed pre-treat-
ment, at 45 days, and at 3 months to assess uterine and
fibroid volume, the latter reducing by around 50% in
both groups [29].
The selective progesterone receptor modulator asoprisnil
(10 and 25 mg daily for 3 months) has been studied in
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women with symptomatic fibroids scheduled for hyster-
ectomy. Uterine blood flow (determined by resistance
index and pulsatility index) and volumes of the largest
fibroid and the uterus were assessed. The intensity and
frequency of menstrual bleeding were recorded on a
menstrual pictogram. The increased pulsatility index and
the significantly increased resistance index observed
indicated a decrease in uterine artery blood flow.
Analysis of menstrual pictogram scores showed a
significant decrease in frequency and intensity of
bleeding compared with placebo. Further studies are
required to evaluate safety and efficacy of asoprisnil
when administered for a longer term [30].
Implications for clinical practice
There is an unmet need for a pharmacological agent that
would result in fibroid shrinkage and reduce menstrual
blood loss whilst maintaining fertility and oestrogenic
state. The ideal treatment would be minimally invasive,
cost-effective, efficacious, tolerable with minimal side
effects, and have a low incidence of fibroid recurrence.
This would significantly reduce the number of major
abdominal surgical procedures required for this com-
mon gynaecological complaint.
Until such time, minimally invasive procedures offer a
number of advantages over open abdominal surgery;
with hysteroscopic resection, anaesthetic can often be
avoided, and with laparoscopic myomectomy recovery
time is quicker and post-operative pain is reduced.
The decision regarding optimal management for the
patient is based on a number of factors: fertility desire,
past medical and surgical history, the size of the fibroids
and the patient’s preference and lifestyle (occupation
and family; can she afford the time spent in hospital
associated with hysterectomy and the recovery time at
home thereafter?). Risks and benefits of each option
must be carefully explained. A recent study has shown
that symptoms, particularly of pain and bleeding,
determine the choice for intervention rather than the
size and number of fibroids [18].
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